Novavax, Inc. (NASDAQ:NVAX) does about 6.68M shares in volume on a normal day but saw 4776797 shares change hands in the recent trading day. The company now has a market cap of 1.56B USD. Its current market price is $9.74, marking a decrease of -1.76% compared to the previous close of $9.92. The 52 week high reached by this stock is $23.86 whilst the lowest price level in 52 weeks is $3.53. The script in recent trading has seen the stock touch a high of $174 and a low of $14.
Novavax, Inc. (NVAX) has a 20-day trading average at $11.88 and the current price is -59.16% off the 52-week high compared with 175.87% distance from its 52-week low. The 50-day simple moving average of the closing price is $12.22 and its 200-day simple moving average is $9.67. If we look at the stock’s price movements over the week, volatility stands at 3.43%, which increases to 7.31% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 32.79 to suggest the stock is neutral.
16 analysts observing the Novavax, Inc. (NVAX) stock have set the 12-month price targets for the company’s shares at between $14 and $174. The consensus objective for the share price is $17.60, suggesting that the stock has a potential upside of 44.66% over the period. The median price target is 55.73% away from the current levels at $22.
FactSet Research has provided data showing that 16 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 10 analysts have rated it as a buy and 6 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 30, 2024 when JP Morgan downgraded the stock to “Underweight” and issued a price target of $8. BofA Securities upgraded its price target at $4-$12.
The current price level is -17.99%, -20.27%, and 0.82% away from its SMA20, SMA50, and SMA200 respectively, with the NVAX price moving above the 50-day SMA on current market day. Novavax, Inc. (NVAX) stock is down -4.27% over the week and -19.76% over the past month. Its price is 103.02% year-to-date and 55.42% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -1.26 above consensus estimates by 0.57. The company’s next earnings report forecasts estimating quarterly EPS at -0.83 and -0.81 for whole year. Expected sales for next quarter are $192.07M, which analysts say will come at $761.46M for the current fiscal year and next year at $545.93M. In addition, estimates put the company’s current quarterly revenue at an average of $65.77M.
Its 12-month price target is $22. To reach the target analysts have set, the stock logically needs to grow 44.66 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $14, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $174.
Outstanding shares total 160.09M with insiders holding 4.38% of the shares and institutional holders owning 54.19% of the company’s common stock. The forward price to earnings ratio is 273.89. The beta has a value of 2.06. Price to sales ratio is 1.58.
